How to Host FDA Investigators

Understand How the Inspection Proceeds

Understanding the inspection process helps teams respond calmly and maintain control. Investigators may hold opening discussions, tour operations, review records, interview personnel, and follow evidence across quality systems. Each request usually supports the assigned scope or addresses information identified during the review. Knowing why an investigator asks a question helps employees locate relevant evidence and avoid speculation. Teams should listen carefully, clarify unclear requests, and provide accurate information through established communication channels. A mock FDA inspection allows personnel to practise these interactions before the Agency arrives. FDA Consulting can also explain common inspection approaches and test whether internal procedures work under pressure. Preparation cannot remove every uncertainty. However, it can reduce avoidable stress, disorganisation, inconsistent responses, and confusion throughout the inspection.

Pre-Inspection Preparation: Before the Investigator Arrives

Inspections may occur without advance notice. Therefore, organisations should maintain these arrangements as part of routine inspection readiness.

Designate a Host and Escort

• Appoint a knowledgeable inspection lead with sufficient authority to coordinate responses and make timely decisions.
• Select the person based on competence and authority, rather than title alone.
• Assign a trained escort to accompany each investigator without obstructing authorised inspection activities.
• Identify alternate hosts and escorts, and maintain their current contact information.

Prepare the Inspection Support Rooms

• Establish a front room for Agency interactions and a separate inspection support room, commonly called the back room.
• Staff the back room with Quality, Regulatory, document control, IT, and subject-matter experts as needed.
• Maintain a controlled log for questions, document requests, reviews, releases, and outstanding commitments.
• Test the process through an FDA mock inspection. FDA Consulting can independently assess its effectiveness under realistic conditions.

Strengthen Document Control

• Confirm that required records remain complete, accurate, legible, attributable, and readily retrievable.
• Verify that current procedures are approved and effective. Retain superseded records for the applicable retention period.
• Ensure signatures and dates appear where required.
• Never create, alter, conceal, or backdate records for inspection preparation.
• Assess which electronic records and signatures fall under Part 11 and applicable predicate-rule requirements.
• Maintain secure, reliable, and appropriately controlled electronic systems where those requirements apply.

During the Inspection

Maintain an organised response process without delaying or restricting authorised activities. FDA Consulting can test this process through an FDA mock inspection before the Agency arrives.

Respond to Requests Promptly

• Route requests through the back room for tracking and review without creating unreasonable delays.
• Record each request, responsible owner, delivery time, and status in the document request log.
• Provide responsive records promptly, or explain the reason and expected delivery time.
• Ensure copies remain complete, accurate, legible, unchanged, and traceable to their source.
• Never remove pages, alter metadata, annotate originals, or create missing records during the inspection.
• Maintain a copy of everything provided to the investigator.

Maintain a Professional Tone

• Remain courteous, factual, responsive, and cooperative throughout the inspection.
• Do not argue, speculate, guess, or provide unsupported explanations.
• When uncertain, say, “We will verify that information and respond accurately.”
• Correct misunderstandings professionally and support explanations with objective evidence.
• The designated scribe should maintain a contemporaneous inspection log.
• Do not make audio recordings without appropriate consent and legal review.

Keep Communication Clear

• Answer each question directly and provide complete, truthful, and responsive information.
• Clarify ambiguous requests before retrieving or presenting records.
• Avoid volunteering unrelated information, but never conceal, mislead, or withhold responsive material.
• Document significant questions, responses, requests, and commitments as accurately as practicable.
• Use exact quotations only when the scribe can record them reliably.

Daily Close-Out

Agency procedures call for daily discussions with management regarding significant findings and outstanding matters. Use these discussions to ask:

• Which topics and systems did you review today?
• Did you identify any concerns or discussion items?
• Are any document requests or questions still outstanding?
• Which areas do you expect to review tomorrow?
• Does the proposed schedule require specific personnel or records?

Afterwards, conduct an internal debrief. Assign actions, reconcile notes, update request logs, and prepare required personnel for the following day.

Post-Inspection Actions

Post-inspection work should begin immediately and follow a documented, risk-based process. CIRG FDA Consulting can support response strategy and later test remediation through an FDA mock inspection.

Form FDA 483 Response, If Issued

The Agency encourages organisations to respond within 15 business days after Form FDA 483 issuance. A comprehensive response should:

• Address every observation separately and reference its exact wording.
• Describe immediate corrections, containment measures, and actions already completed.
• Explain the investigation, root cause analysis, systemic scope, and potential product impact.
• Assess whether similar conditions affect other products, processes, systems, or facilities.
• Identify corrective actions or CAPAs, responsible owners, interim controls, and target completion dates.
• Include objective evidence supporting completed corrections and corrective actions.
• Explain why incomplete actions require additional time and provide realistic completion dates.
• Commit to appropriate progress updates when actions extend beyond the initial response period.
• Avoid claiming closure before the organisation verifies effectiveness.

Note: A late or inadequate response does not automatically cause a Warning Letter. However, the Agency may proceed without reviewing a response received after the applicable period.

Internal CAPA Review

• Document and evaluate every written observation and significant verbal discussion item.
• Determine whether each issue requires correction, investigation, CAPA, change control, or another quality-system process.
• Do not initiate a CAPA automatically for every observation.
• Evaluate recurrence, systemic impact, product risk, and related processes.
• Update procedures, training, validation records, and risk-management files when the investigation supports those actions.
• Do not rely on retraining alone unless evidence identifies training as a relevant contributing cause.
• Verify implementation and effectiveness before closing corrective actions.

Received Significant Form FDA 483 Observations?

If your organisation receives one or more significant inspectional observations, contact CIRG as soon as possible. Early FDA Consulting support provides time to evaluate the observations, preserve evidence, and prepare a coordinated response. Prompt contact is especially important when CIRG did not participate in the inspection’s back-room support team. We must first understand what the investigator reviewed, requested, discussed, and received.

Useful records include scribe notes, request logs, documents provided, daily summaries, and management’s close-out notes. CIRG can then assess systemic scope, root causes, corrective actions, supporting evidence, and realistic completion dates. Do not submit a rushed response or delay corrective action while seeking assistance. When practicable, engage us before submitting your Form FDA 483 response. A previous mock FDA inspection may support readiness, but it does not replace a careful response review. Your organisation remains responsible for every submission and compliance decision.

FDA Inspection “War Room” (Back Room) Setup

During an FDA inspection, the “war room”, or back room, functions as the organisation’s internal coordination hub. It remains separate from the front room, where designated personnel communicate with investigators. The back-room team tracks requests, retrieves records, verifies accuracy, and coordinates timely responses. This structure represents an industry practice, not an Agency requirement. A back room must never delay, limit, or obstruct authorised inspection activities. FDA Consulting can test the arrangement through a mock FDA inspection before the Agency arrives.

Core Personnel

• Back-Room Leader: Appoint someone with high authority, extensive quality-system knowledge, and strong decision-making ability.
• Inspection Coordinator: This person prioritises requests, assigns owners, manages deadlines, and escalates potential compliance concerns.
• Document Control Specialist: Locates complete records and verifies document identity, version, legibility, and responsiveness.
• Back-Room Scribe: Tracks requests, decisions, document flow, delivery times, questions, and outstanding commitments.
• Subject-Matter Experts: Locate technical evidence and prepare accurate explanations when requested.
• SMEs may receive context about a request, but no one should script, influence, or rehearse misleading answers.

Support Roles

• Runner: Transfers records between rooms and confirms delivery through the request log.
• Communication Liaison: Keeps leadership informed and coordinates internal updates without disrupting the inspection.
• Technical Support: Manages authorised access to LIMS, ERP, QMS, and other electronic systems.
• Technical personnel should preserve metadata, audit trails, access controls, and original record content.
• Interpreter or Translator: Supports accurate communication and document translation when language assistance becomes necessary.

Key Functions of the War Room

• Document Preparation: Gather and verify complete, accurate, legible, and responsive records before release.
• Response Alignment: Ensure explanations remain truthful, evidence-based, and consistent with company records.
• SME Preparation: Explain the request’s context and remind SMEs to answer directly without speculation.
• Real-Time Tracking: Record requests, responses, documents provided, questions asked, and outstanding actions.
• Issue Escalation: Notify authorised leadership promptly about significant concerns or potential inspectional observations.
• Confidentiality Review: Identify privacy, trade-secret, and potential privilege concerns through established procedures.
• Confidentiality review must not improperly delay or withhold records that the Agency may lawfully inspect.

Best Practices

• Keep the back room calm and organised. Uncontrolled pressure can increase errors and inconsistent responses.
• Use a request-tracking system to monitor owners, priorities, deadlines, reviews, and delivery status.
• Assign an authorised reviewer to confirm completeness and responsiveness before releasing records.
• Never alter, omit, sanitise, recreate, or backdate records during the review process.
• Maintain an exact copy of every record and electronic file provided to the investigator.
• Route communications through the designated company representative where practical.
• Do not obstruct authorised interviews, employee questions, record access, or facility access.

For complete preparation, hosting, and response guidance, [click here for the full FDA Inspection Playbook].